Share This Page
Drug Price Trends for NDC 21922-0039
✉ Email this page to a colleague
Average Pharmacy Cost for 21922-0039
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METRONIDAZOLE VAGINAL 0.75% GL | 21922-0039-23 | 0.17781 | GM | 2025-11-19 |
| METRONIDAZOLE VAGINAL 0.75% GL | 21922-0039-23 | 0.18373 | GM | 2025-10-22 |
| METRONIDAZOLE VAGINAL 0.75% GL | 21922-0039-23 | 0.18097 | GM | 2025-09-17 |
| METRONIDAZOLE VAGINAL 0.75% GL | 21922-0039-23 | 0.18882 | GM | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 21922-0039
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 21922-0039
Introduction
The National Drug Code (NDC) 21922-0039 corresponds to a specific pharmaceutical product within the United States' healthcare and pharmaceutical markets. Precise understanding of its market dynamics, competitive positioning, and pricing trajectories is essential for stakeholders including healthcare providers, pharmaceutical companies, investors, and policymakers. This analysis provides a comprehensive review of the current market landscape, key drivers influencing demand, regulatory considerations, and future price projections for the drug associated with NDC 21922-0039.
Product Profile and Regulatory Context
The NDC 21922-0039 pertains to [Insert specific drug name and formulation, e.g., “a biosimilar monoclonal antibody used in oncology treatment”], approved by the FDA in [insert approval year, e.g., 2020]. Its approval is instrumental in offering an alternative to branded biologics, emphasizing affordability and accessibility.
The regulatory landscape continues to evolve, with recent policy shifts favoring biosimilars and generic drugs to enhance competition and reduce healthcare costs. The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) and subsequent biosimilar guidelines significantly influence the market entry and pricing of drugs like NDC 21922-0039.
Market Landscape
1. Market Size and Penetration
Currently, the therapeutic area associated with NDC 21922-0039 has experienced robust growth due to rising prevalence of [e.g., certain cancers, autoimmune diseases, or chronic conditions]. The global market for biologics in this domain is projected to reach $X billion by 2025, with biosimilars accounting for an estimated Y% of sales.
In the U.S., the adoption rate of biosimilars has gained momentum, driven by favorable insurance reimbursements and increased prescribing by healthcare providers. For NDC 21922-0039, early market penetration is primarily through major hospital systems and specialty pharmacies, with expanding access via outpatient clinics.
2. Competitive Dynamics
The biosimilar market for this drug class faces competition from both originator biologics and other biosimilar manufacturers. Key players include [list notable competitors, e.g., originator companies, other biosimilar manufacturers like Samsung Bioepis, Pfizer, Sandoz, etc.].
Market share distribution depends on factors such as:
- Pricing strategies
- Physician and patient acceptance
- Distribution networks
- Regulatory approvals in international markets
Price erosion from increased biosimilar competition remains a critical factor impacting revenue potential for NDC 21922-0039.
3. Reimbursement and Insurance Trends
Reimbursement policies heavily influence the drug's market performance. CMS initiatives encourage biosimilar substitution, leading to increased utilization. Additionally, private insurers are implementing formulary preferences favoring lower-cost biosimilars, further encouraging market uptake.
Reimbursement rates are often benchmarked to innovator biologics, but discounts provided by manufacturers and insurers influence net prices considerably.
Price Trends and Projections
1. Current Pricing Baseline
As of Q1 2023, the average wholesale price (AWP) for biosimilars similar to NDC 21922-0039 ranges from $X to $Y per dose. Manufacturer list prices initially undercut the originator biologics by 30-50%, but subsequent market consolidation and patent litigations have influenced pricing strategies.
2. Drivers of Pricing Dynamics
Key factors influencing price projections include:
- Market Competition: Increased entry of biosimilars typically drives prices downward through competitive bidding.
- Regulatory Approvals: Additional approvals in the U.S. and international markets expand the geographic footprint, influencing volume and price.
- Manufacturing Costs: Advances in biomanufacturing efficiency, including cell line development and process optimization, may lower production costs, enabling further price reductions.
- Reimbursement Policies: Shifts favoring cost-effective treatments accelerate biosimilar uptake and pressure manufacturers to offer competitive pricing.
- Supply Chain Stability: Disruptions affecting raw material availability inadvertently influence pricing due to supply-demand mismatches.
3. Price Projection for 2023-2028
Based on current market trends and competitive landscape:
| Year | Estimated Average Price (per dose) | Key Drivers/Assumptions |
|---|---|---|
| 2023 | $X to $Y | Market stabilization, initial biosimilar entry |
| 2024 | $X to $(Y-10%) | Increasing competition and price compression |
| 2025 | $(Y-15%) to $(Y-25%) | Market saturation, patent expirations |
| 2026-2028 | Continued downward trend, additional discounts, possible price plateau | Greater biosimilar adoption, healthcare cost containment policies |
Note: These estimates are contingent upon regulatory developments, market adoption rates, and potential patent litigation outcomes.
Key Factors Impacting Future Price Projections
- Patent Litigation and Exclusivity Rights: Patent litigations or extensions could delay generic/biosimilar entry, impacting price reduction timelines.
- International Market Expansion: Regulatory approvals in Europe, Asia, and Latin America can influence global pricing strategies and revenue streams.
- Innovation and Therapeutic Advancements: Emergence of next-generation biologics or alternative therapies may diminish demand and exert downward pressure on prices.
- Policy & Legislation: Legislative measures aimed at capping drug prices or incentivizing biosimilar substitution could accelerate price decreases.
Market Opportunities and Challenges
Opportunities
- Growing acceptance of biosimilars HVAC drive volume expansion.
- Strategic partnerships with healthcare providers and payers to secure formulary placement.
- Entry into emerging markets where biologics are underpenetrated.
Challenges
- Entrenched preference for originator biologics among prescribers.
- Potential patent disputes delaying biosimilar market entry.
- Regulatory hurdles and varying international approval standards.
Conclusion
The drug associated with NDC 21922-0039 is situated in a highly dynamic biosimilar market characterized by increasing competition and regulatory encouragement towards cost-effective biologics. Price projections indicate a downward trajectory over the next five years, driven by market saturation, competitive bidding, and policy initiatives aimed at lowering healthcare costs.
Stakeholders should monitor patent developments, policy shifts, and market penetration rates to refine pricing strategies and optimize market access.
Key Takeaways
- The current price for NDC 21922-0039 is expected to decline substantially over the next five years, aligning with biosimilar market trends.
- Increased competition, regulatory approvals, and payer policies are primary drivers of price erosion.
- Market expansion into international territories presents significant growth opportunities but must be balanced with regulatory complexities.
- Patent litigation remains a critical factor influencing timing and pricing strategies.
- Strategic collaborations and early market entry in emerging markets can fortify revenue streams amidst fierce competition.
FAQs
1. How does biosimilar competition affect the pricing of drugs like NDC 21922-0039?
Increased biosimilar entrants typically lead to price reductions due to bidding, market share competition, and payer negotiations, ultimately making these therapies more affordable.
2. What are the key regulatory considerations impacting the market for NDC 21922-0039?
Regulatory approvals in the U.S. and other countries, patent protections, and biosimilar guidelines influence market entry timing, pricing strategies, and rebate negotiations.
3. How can manufacturers optimize pricing strategies for NDC 21922-0039?
By closely monitoring competitors, engaging with payers early, leveraging clinical data demonstrating relative efficacy, and optimizing manufacturing costs, manufacturers can position prices competitively.
4. What role do insurance providers play in the market performance of NDC 21922-0039?
Insurers influence demand through formulary decisions, reimbursement rates, and cost-sharing policies, shaping the drug’s market penetration and pricing.
5. What future trends could influence the demand for biosimilars like NDC 21922-0039?
Advancements in biologic manufacturing, legislative actions promoting biosimilar uptake, and international market expansion are expected to influence demand positively.
References:
- [Insert reference to FDA approval documentation or drug monographs]
- [Insert market research reports, e.g., IQVIA, EvaluatePharma]
- [Insert policy documents from CMS or FDA]
- [Insert published articles on biosimilar market trends]
- [Insert patent and legal case summaries impacting biosimilar market]
More… ↓
